$BLRX

BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.

BioLineRx (BLRX) reported 2Q 2026 revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 clinical trial is progressing, with new data showing synergistic effects with a PARP inhibitor. BioLineRx raised $3.75 million in capital to support development. The trial's Phase I/IIa results are expected in 1H 2027.

BioLineRx reported Q2 2026 revenue of $0.3M, unchanged year-over-year, with a net loss of $4.3M. Shares rose 4.49% post-earnings. GLIX1 clinical trials are progressing, and the company secured $3.75M in financing. Cash reserves were $13.1M at quarter-end.

BioLineRx (BLRX) reported Q2 2026 earnings with $0.00 EPS, matching estimates. Revenue was $294,000, down from $304,000 in Q2 2025. The company had a net loss of $4.3M and $13.1M in cash and equivalents. BioLineRx is focused on oncology and rare disease treatments.

BioLineRx Ltd. (BLRX) furnished an SEC Form 6-K — earnings release. Exhibit 1 For Immediate Release BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data

BioLineRx (BLRX) shares fell 4.4% premarket after announcing a $3.75M share offering at $2.78 per ADS, below recent trading levels. The company plans to use proceeds for R&D and corporate purposes. The offering includes warrants for additional shares and is expected to close by August 31, 2026. BLRX is developing therapies in oncology and rare diseases, with its lead asset in a Phase 1/2a trial.

BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced a $3.75M registered direct offering of 1.35M ADSs at $2.78 each, with warrants for 2.02M more. Proceeds will fund R&D and working capital. Closing expected Aug 31, 2026. The company also amended outstanding warrants, reducing the exercise price to $2.78 and extending expiration to 2031.

BioLineRx Ltd. director Sandra Panem filed an initial ownership report, Form 3, detailing a significant number of employee stock options to purchase ordinary shares. These options include various blocks with different exercise prices and expiration dates ranging from 2026 to 2034. Footnotes indicate that older grants through 2024 are fully vested, while a substantial portion of a more recent October 2024 grant will vest quarterly, conditional on continued service.

BioLineRx Ltd. director Cohen Gal Avraham has filed an initial ownership report detailing employee stock options for 2,055,000 ordinary shares. These options have an exercise price of $0.052 per share and expire on August 14, 2034, granted under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remainder vesting in seven equal quarterly installments, subject to continued service.

BioLineRx secured a full arbitration victory in a dispute with Biokine Therapeutics over alleged unpaid amounts related to a motixafortide licensing agreement. The arbitrator denied Biokine's $7.2 million claim and awarded BioLineRx legal expenses, resolving a financial and legal uncertainty for the biopharmaceutical company. This decision strengthens BioLineRx's financial position and clarifies its obligations regarding the motixafortide program.